Patents by Inventor Darren Wakefield

Darren Wakefield has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9107957
    Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted melittin delivery peptides. Delivery peptides provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery peptides.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: August 18, 2015
    Assignee: Arrowhead Madison Inc.
    Inventors: David B Rozema, David L Lewis, Darren Wakefield, Eric Kitas, Philipp Hadwiger, Jon Wolff, Ingo Röhl, Peter Mohr, Torsten Hoffmann, Kerstin Jahn-Hofmann, Hans Martin Mueller, Günther Ott, Andrei V Blokhin, Jonathan D Benson, Jeffrey C Carlson
  • Publication number: 20130281658
    Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted melittin delivery peptides. Delivery peptides provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery peptides.
    Type: Application
    Filed: June 25, 2013
    Publication date: October 24, 2013
    Inventors: David B Rozema, David L Lewis, Darren Wakefield, Eric Kitas, Philipp Hadwiger, Jon Wolff, Ingo Röhl, Peter Mohr, Torsten Hoffmann, Kerstin Jahn-Hofmann, Hans Martin Mueller, Günther Ott, Andrei V Blokhin, Jonathan D Benson, Jeffrey C Carlson
  • Publication number: 20130190484
    Abstract: The present invention is directed compositions for delivery of RNA interference (RNAi) polynucleotides to cells in vivo. The compositions comprise amphipathic membrane active polyamines reversibly modified with enzyme cleavable dipeptide-amidobenzyl-carbonate masking agents. Modification masks membrane activity of the polymer while reversibility provides physiological responsiveness. The reversibly modified polyamines (dynamic polyconjugate or DPC) are further covalently linked to an RNAi polynucleotide or co-administered with a targeted RNAi polynucleotide-targeting molecule conjugate.
    Type: Application
    Filed: March 15, 2013
    Publication date: July 25, 2013
    Applicant: ARROWHEAD MADISON INC.
    Inventors: David Rozema, David Lewis, Darren Wakefield, Eric Kitas, Philipp Hadwiger, Jon Wolff, Ingo Roehl, Peter Mohr, Torsten Hoffmann, Kerstin Jahn-Hofmann, Hans Martin Mueller, Guenther Ott, Andrei Blokhin, Jeffrey Carlson, Jonathan Benson
  • Patent number: 8217015
    Abstract: We describe pH-sensitive endosomolytic polymers, delivery particles containing pH-sensitive endosomolytic polymers. The described particles are capable of delivering polynucleotides to cells from the peripheral circulation with subsequent release from endosomes. The endosomolytic polymers are inactive outside the cell but disrupt membranes upon exposure to an acidified endosomal compartment.
    Type: Grant
    Filed: April 1, 2004
    Date of Patent: July 10, 2012
    Assignee: Arrowhead Madison Inc.
    Inventors: David B. Rozema, Darren Wakefield
  • Patent number: 7871818
    Abstract: We describe a class of polymaleic anhydride polymers capable of disrupting cell membranes. Co-delivery of these polymers with biologically active compounds increases cellular cytoplasmic delivery of the compounds.
    Type: Grant
    Filed: January 27, 2004
    Date of Patent: January 18, 2011
    Assignee: Roche Madison Inc.
    Inventors: David B. Rozema, Darren Wakefield
  • Patent number: 7816337
    Abstract: Described is a process for delivering a biologically active compound to a cell by reversibly linking the compound to a membrane active polymer. In particular, polymer-polynucleotide conjugates are described. Methods for reversibly modifying the polymers to decrease cellular toxicity and improve efficacy are provided.
    Type: Grant
    Filed: February 17, 2004
    Date of Patent: October 19, 2010
    Assignee: Roche Madison Inc.
    Inventors: David B. Rozema, Darren Wakefield, Jon A Wolff, Kirk Ekena, James E. Hagstrom
  • Patent number: 7682626
    Abstract: A class of polymers for delivery of polynucleotides to cells in described. More specifically, amphiphilic polyvinylethers and compositions containing amphiphilic polyvinylethers are described.
    Type: Grant
    Filed: February 5, 2004
    Date of Patent: March 23, 2010
    Assignee: Roche Madison Inc.
    Inventors: David B. Rozema, Darren Wakefield
  • Patent number: 7442764
    Abstract: An process for the reversible modification of an amine-containing compound is described. Modification of the compound can be used to facilitate delivery of molecules to cells in vitro and in vivo or to alter interactions or activities the compounds. The described modifiers can also be utilized as cross-linkers.
    Type: Grant
    Filed: December 20, 2005
    Date of Patent: October 28, 2008
    Assignee: Mirns Bio Corporation
    Inventors: David B. Rozema, Darren Wakefield, Jon A. Wolff, Kirk Ekena, James E. Hagstrom
  • Publication number: 20080132689
    Abstract: Described are ortho carboxy phenol derived acetals and compositions containing ortho carboxy phenol derived acetals which are useful for delivering biologically active compounds to cells. The acetals can be used to reversibly link up to three different molecules and have rapid hydrolysis kinetics in conditions which are present in a cell as well as in vivo. Cleavage of the acetal enhances delivery of the biologically active compound.
    Type: Application
    Filed: January 29, 2008
    Publication date: June 5, 2008
    Inventors: David B. Rozema, Darren Wakefield
  • Patent number: 7348453
    Abstract: Described are ortho carboxy phenol derived acetals and compositions containing ortho carboxy phenol derived acetals which are useful for delivering biologically active compounds to cells. The acetals can be used to reversibly link up to three different molecules and have rapid hydrolysis kinetics in conditions which are present in a cell as well as in vivo. Cleavage of the acetal enhances delivery of the biologically active compound.
    Type: Grant
    Filed: August 30, 2004
    Date of Patent: March 25, 2008
    Assignee: Mirus Bio Corporation
    Inventors: David B. Rozema, Darren Wakefield
  • Publication number: 20070036865
    Abstract: We describe pH-sensitive endosomolytic polymers, delivery particles containing pH-sensitive endosomolytic polymers. The described particles are capable of delivering polynucleotides to cells from the peripheral circulation with subsequent release from endosomes. The endosomolytic polymers are inactive outside the cell but disrupt membranes upon exposure to an acidified endosomal compartment.
    Type: Application
    Filed: September 19, 2006
    Publication date: February 15, 2007
    Applicant: MIRUS BIO CORPORATION
    Inventors: David Rozema, Darren Wakefield, Jon Wolff, Vladimir Budker, Tatyana Budker, Sean Monahan, Vladimir Trubetskoy, James Hagstrom, Aaton Loomis, Paul Slattum
  • Publication number: 20060154867
    Abstract: We describe compounds that bind to and are internalized by hepatocytes. Association of these compounds to other molecules or complexes can be used to target the molecules or complexes to hepatocytes in vivo or in vitro.
    Type: Application
    Filed: January 20, 2006
    Publication date: July 13, 2006
    Inventors: Alexander Sokoloff, So Wong, Jon Wolff, Sean Monahan, James Ludtke, Lori Higgs, Darren Wakefield, Magdolna Sebestyen
  • Patent number: 7071163
    Abstract: We describe compounds that bind to and are internalized by hepatocytes. Association of these compounds to other molecules or complexes can be used to target the molecules or complexes to hepatocytes in vivo or in vitro.
    Type: Grant
    Filed: August 4, 2003
    Date of Patent: July 4, 2006
    Assignee: Mirus Bio Corporation
    Inventors: Alexander V. Sokoloff, So Wong, Jon A. Wolff, Sean D. Monahan, James Ludtke, Lori Higgs, Darren Wakefield, Magdolna G. Sebestyén
  • Publication number: 20060122096
    Abstract: An process for the reversible modification of an amine-containing compound is described. Modification of the compound can be used to facilitate delivery of molecules to cells in vitro and in vivo or to alter interactions or activities the compounds. The described modifiers can also be utilized as cross-linkers.
    Type: Application
    Filed: December 20, 2005
    Publication date: June 8, 2006
    Inventors: David Rozema, Darren Wakefield, Jon Wolff, Kirk Ekena, James Hagstrom
  • Patent number: 7019113
    Abstract: An process for the reversible modification of membrane interaction of a compound is described. Modification of membrane interaction can be used to facilitate delivery of molecules to cells in vitro and in vivo. The described modifiers, which are used to reversibly inactivate the membrane active compounds, can also be utilized as cross-linkers or to reverse the charge of a molecule.
    Type: Grant
    Filed: May 23, 2003
    Date of Patent: March 28, 2006
    Assignee: Mirus Bio Corporation
    Inventors: David B. Rozema, Darren Wakefield, Jon A. Wolff, Kirk Ekena, James E. Hagstrom
  • Publication number: 20060063257
    Abstract: Polyampholyte are able to condense nucleic acid to form small complexes which can be utilized in the delivery of nucleic acid to mammalian cells. The polyampholytes can be formed prior to interaction with nucleic acid or they can be formed in the presence of nucleic acid. Stabilized polycation/nucleic acid complexes can be modified to reduce the positive charge of the polycation and add targeting ligands without destabilizing the complex. The resultant particles retain their small size and are more effective in delivery of nucleic acid to cells in vivo.
    Type: Application
    Filed: October 21, 2005
    Publication date: March 23, 2006
    Inventors: Darren Wakefield, David Rozema, Jon Wolff, Vladimir Trubetskoy, James Hagstrom, Vladimir Budker, Jason Klein, So Wong
  • Publication number: 20050250683
    Abstract: An process for the reversible modification of membrane interaction of a compound is described. Modification of membrane interaction can be used to facilitate delivery of molecules to cells in vitro and in vivo. The described modifiers, which are used to reversibly inactivate the membrane active compounds, can also be utilized as cross-linkers or to reverse the charge of a molecule.
    Type: Application
    Filed: May 23, 2003
    Publication date: November 10, 2005
    Inventors: David Rozema, Darren Wakefield, Jon Wolff, Kirk Ekena, James Hagstrom
  • Publication number: 20050170505
    Abstract: Polyampholyte are able to condense nucleic acid to form small complexes which can be utilized in the delivery of nucleic acid to mammalian cells. The polyampholytes can be formed prior to interaction with nucleic acid or they can be formed in the presence of nucleic acid. Stabilized polycation/nucleic acid complexes can be modified to reduce the positive charge of the polycation and add targeting ligands without destabilizing the complex. The resultant particles retain their small size and are more effective in delivery of nucleic acid to cells in vivo.
    Type: Application
    Filed: January 28, 2005
    Publication date: August 4, 2005
    Inventors: Darren Wakefield, David Rozema, Jon Wolff, Vladimir Trubetskoy, James Hagstrom, Vladimir Budker, Jason Klein, So Wong
  • Publication number: 20050054604
    Abstract: Described are ortho carboxy phenol derived acetals and compositions containing ortho carboxy phenol derived acetals which are useful for delivering biologically active compounds to cells. The acetals can be used to reversibly link up to three different molecules and have rapid hydrolysis kinetics in conditions which are present in a cell as well as in vivo. Cleavage of the acetal enhances delivery of the biologically active compound.
    Type: Application
    Filed: August 30, 2004
    Publication date: March 10, 2005
    Inventors: David Rozema, Darren Wakefield
  • Publication number: 20040198687
    Abstract: We describe pH-sensitive endosomolytic polymers, delivery particles containing pH-sensitive endosomolytic polymers. The described particles are capable of delivering polynucleotides to cells from the peripheral circulation with subsequent release from endosomes. The endosomolytic polymers are inactive outside the cell but disrupt membranes upon exposure to an acidified endosomal compartment.
    Type: Application
    Filed: April 1, 2004
    Publication date: October 7, 2004
    Inventors: David B. Rozema, Darren Wakefield, Jon A. Wolff, Vladimir Trubetskoy, Vladimir G. Budker, James E. Hagstrom, Aaron G. Loomis, Sean D. Monahan, Paul M. Slattum